Expanding Horizons in the Treatment of Mantle Cell Lymphoma: Ibrutinib a Novel BTK-targeting Inhibitor

International Journal of Basic & Clinical Pharmacology
doi 10.5455/2319-2003.ijbcp20140231
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Medip Academy

Related search

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK Cell Effector Function in Patients With Mantle Cell Lymphoma

Haematologica
Hematology
2019English

Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2017English

Ibrutinib Plus Palbociclib Has Efficacy in Mantle Cell Lymphoma

Cancer Discovery
Oncology
2019English

Splenectomy in the Treatment of Mantle Cell Lymphoma

Hematology & blood transfusion: interdepartamental collection
2016English

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

British Journal of Haematology
Hematology
2018English

Targeting WNT Pathway in Mantle Cell Lymphoma-Initiating Cells

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2015English

New Treatment Options in Mantle Cell Lymphoma

European Oncology and Haematology
OncologyHematology
2015English

Copanlisib and Volasertib Overcome Ibrutinib-Venetoclax Resistance via Targeting Pi3k-Akt Signaling and G2/M Cell Cycle Transition in Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy